Gufic BioSciences Ltd (GUFICBIO)
🎯 Key Takeaways
- Gufic BioSciences is transitioning from a mature domestic-focused API manufacturer to a globally integrated, IP-driven specialty injectables and reproductive health player with international regulatory momentum. Management is actively building a scalable, high-margin global footprint through strategic regulatory approvals, capacity expansion, and geographic diversification into Southeast Asia via its new Philippine subsidiary.
- Revenue grew 3.6% QoQ to ₹261 in Q1FY27.
- ⚠️ 1) Regulatory delays in US FDA inspection or approval could stall international revenue growth. 2) Execution risks in scaling capacity to 30% utilizat
- Market Cap
- ₹4,225
- P/E Ratio
- 57.5
- P/B Ratio
- 6.35
- ROE
- 11.1%
- ROCE
- 12.9%
- Debt/Equity
- 0.58
- Div Yield
- 0.02%
- Promoter
- 72.5%
📖 The Story
Gufic BioSciences is transitioning from a mature domestic-focused API manufacturer to a globally integrated, IP-driven specialty injectables and reproductive health player with international regulatory momentum. Management is actively building a scalable, high-margin global footprint through strategic regulatory approvals, capacity expansion, and geographic diversification into Southeast Asia via its new Philippine subsidiary.
📰 What's Happening
In Q1 FY27, Gufic reported 69.9% YoY revenue growth to ₹260.8 crores, driven by strong performance in reproductive health and injectables, with EBITDA margins supporting capacity expansion. Management highlighted completion of EU GMP audit, submission of US FDA filing for a client, and attainment of WHO GMP certification for its Indore facility. The board approved incorporation of a Philippine subsidiary with up to $250,000 investment to strengthen Southeast Asian distribution and IP management. Re-appointment of Whole-Time Director Pankaj Gandhi until 2031 was approved at the AGM, ensuring leadership continuity. The company is targeting 30% capacity utilization by FY26 and US FDA inspection completion by FY29 to underpin long-term growth in complex injectables and pipeline advancements.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 224 | 237 | 231 | 252 | 261 |
| Operating Profit | 26 | 30 | 25 | 40 | 39 |
| OPM % | 11.4% | 12.7% | 10.9% | 15.7% | 14.9% |
| Net Profit | 13 | 17 | 12 | 22 | 22 |
| EPS | ₹1.30 | ₹1.68 | ₹1.24 | ₹2.18 | ₹2.22 |
Revenue has accelerated sharply, rising from ₹224 crores in Q1 FY25 to ₹260.8 crores in Q1 FY27, with operating margins expanding from 11.4% to 14.9%, reflecting improved efficiency and product mix. Net profit increased to ₹22 crores from ₹13 crores over the same period, indicating margin expansion despite rising operational investments. The company is reinvesting gains into capacity and regulatory milestones, as evidenced by rising OCF and targeted capital deployment toward facility upgrades and international market entry.
🔮 Management Outlook & What's Next
Management projects capacity utilization of 30% by FY26 and aims to complete US FDA inspection by FY29 to support scalable international sales. They emphasize an IP-owned model in complex injectables and ongoing pipeline advancements in fertility and pain management as key growth drivers. The Philippine subsidiary is positioned as a strategic enabler for Southeast Asian market penetration, with statutory approvals expected within 12 months. No formal long-term financial targets beyond operational milestones were disclosed, but regulatory progress and capacity scaling are central to their growth narrative.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 |
| Reserves | 591 | 564 | 655 | 621 |
| Borrowings | 336 | 296 | 385 | 369 |
| Total Liabilities | 1,169 | 1,105 | 1,342 | 1,271 |
| Fixed Assets | 500 | 143 | 491 | 489 |
| Investments | 2 | 2 | 2 | 2 |
| Total Assets | 1,169 | 1,105 | 1,342 | 1,271 |
Equity and reserves have grown steadily from ₹621 crores to ₹655 crores between March 2025 and March 2026, while borrowings increased modestly from ₹336 crores to ₹385 crores, indicating disciplined but active capital deployment. The rise in total assets to ₹1,342 crores aligns with investments in facilities and expansion initiatives. The company maintains a healthy debt-to-equity ratio of 0.58, suggesting sustainable leverage levels as it funds growth through retained earnings and limited external financing.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 | Mar 2026 |
|---|---|---|
| Operating | +123 | +45 |
| Investing | -71 | -31 |
| Financing | -37 | +32 |
| Net Cash Flow | +15 | +46 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 72.5% | 72.5% | 72.5% | 72.5% |
| FII | 0.3% | 0.4% | 0.4% | 0.5% |
| DII | 3.7% | 3.7% | 3.8% | 3.7% |
| Public | 14.4% | 14.1% | 13.9% | 14.0% |
| # Shareholders | 31,420 | 30,362 | 29,223 | 29,753 |
Promoter holding remains stable at 72.5% over the past year, signaling confidence in long-term prospects. FII ownership has slightly increased from 0.34% to 0.46%, while DII participation has risen from 3.66% to 3.83%, suggesting growing institutional interest. The number of public shareholders has declined slightly from 31,420 to 29,753, but this may reflect dematerialization or consolidation rather than exit. No significant selling by promoters or institutions has been observed, and no pledging activity was disclosed.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.41 L Cr | 36.5 | 18.7% | — | 0.05 |
| DIVISLAB | 2.53 L Cr | 86.5 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.85 L Cr | 77.7 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.21 L Cr | 27.0 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.09 L Cr | 99.3 | 20.8% | — | 0.45 |
| DRREDDY | 1.02 L Cr | 31.6 | 10.1% | — | 0.17 |
| MANKIND | 1.01 L Cr | 49.3 | 13.9% | — | 0.38 |
| AUROPHARMA | 97,814 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,274 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) Regulatory delays in US FDA inspection or approval could stall international revenue growth. 2) Execution risks in scaling capacity to 30% utilization while maintaining quality and margins. 3) Integration and operational ramp-up risks associated with the new Philippine subsidiary. 4) Margin pressure if raw material costs rise or competitive pricing emerges in high-growth segments like injectables.
📋 Recent Filings
- Announcement2026-09-28Gufic BioSciences announced that its trading window will close on October 1, 2026, and remain shut until 48 hours after the unaudited financial result…
- 🔴 Announcement2026-09-28Gufic BioSciences announced that Crisil ESG Ratings assigned an overall ESG rating of CRISIL ESG 62 (Category: Strong) for FY 2025-26, reflecting stro…
- 🔴 Announcement2026-09-24Gufic BioSciences disclosed penalties of ₹8,000 and [amount not verified] imposed by BSE and NSE for appointing a director over 75 without shareholder…
- 🔴 Announcement2026-09-08Gufic BioSciences announced that CRISIL reaffirmed its credit ratings on bank facilities, upgrading the total loan amount from Rs. 425 crore to Rs. 51…
- 🟡 Board Meeting2026-09-04Gufic Biosciences held its 42nd AGM on September 4, 2026 via video conference, approving the audited standalone and consolidated financial statements …
- 🟡 Board Meeting2026-09-02Gufic Biosciences announced on September 2, 2026 that Ms. Ami Shah was promoted to Head-Legal while retaining her role as Company Secretary & Complian…
- Announcement2026-08-17Gufic Biosciences announced that an audio recording of its earnings conference call held on August 17, 2026 at 4:30 p.m. is now available on its websi…
- 🟡 Board Meeting2026-08-14Gufic Biosciences announced its August 14, 2026 board meeting outcome, approving unaudited Q1 FY27 financial results and incorporating a Philippine su…
- 🟡 Board Meeting2026-08-14Gufic Biosciences announced board approval to incorporate a Philippine subsidiary, Gufic Philippines Inc., to expand pharmaceutical operations and man…
- 🔴 Financial Results2026-08-14Gufic Biosciences reported Q1 FY27 revenue of [amount context mismatch] crores, up 69.9% YoY, driven by strong growth in reproductive health and injec…
🧠 Analyst's Read
Gufic BioSciences is executing a clear, capital-intensive transformation from a domestic API supplier to a globally integrated specialty pharma player, supported by strong revenue growth, regulatory progress, and strategic expansion. The next 12–24 months will be critical to validate execution against capacity, regulatory, and geographic milestones. Watch for updates on US FDA inspection timelines and Philippine subsidiary progress as key near-term catalysts.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-29.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when GUFICBIO files new disclosures
Track GUFICBIO filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track GUFICBIO — FreeFree account · 2 AI queries/day